GABA

Introducing Calm Mood: Breakthrough Solution for Natural Stress Relief

Retrieved on: 
Thursday, November 9, 2023

CHARLESTON, S.C., Nov. 9, 2023 /PRNewswire/ -- Healthycell today announced the launch of its latest product, Calm Mood. Developed by physicians and nutritionists, Calm Mood is a revolutionary blend of non-drowsy nutrients designed to support a sense of calm by relaxing the nervous system and promoting the balance of serotonin and dopamine. Calm Mood is a blend of potent ingredients such as Ashwagandha, known for its adaptogenic properties; L-Theanine and GABA, which promote relaxation; 5HTP to support serotonin production; Saffron for mood enhancement; and essential calm-inducing nutrients like Magnesium and B Vitamins. These ingredients are designed to melt away occasional stress and foster a sense of calm.

Key Points: 
  • Developed by physicians and nutritionists, Calm Mood is a revolutionary blend of non-drowsy nutrients designed to support a sense of calm by relaxing the nervous system and promoting the balance of serotonin and dopamine.
  • These ingredients are designed to melt away occasional stress and foster a sense of calm.
  • "Stress relief and mental well-being are critical to our overall health," commented Healthycell CEO Douglas Giampapa, "Our Calm Mood MICROGEL™ supplement is an easy, drug-free way to support a healthy mood and daily stress relief in an ultra-absorbable gel."
  • Calm Mood supports stress relief and neurotransmitter balance.

Thought Leadership & Innovation Foundation (TLI) Sponsors TACA Autism Conference, Showcases Autism Knowledge Gateway

Retrieved on: 
Wednesday, November 1, 2023

“This remarkable event served as a lifeline for families touched by autism, providing them with direct access to renowned experts, The Autism Community in Action (TACA) mentors, sponsors, vendors and like-minded families from across the nation,” says Shawn Murphy, vice president, TLI.

Key Points: 
  • “This remarkable event served as a lifeline for families touched by autism, providing them with direct access to renowned experts, The Autism Community in Action (TACA) mentors, sponsors, vendors and like-minded families from across the nation,” says Shawn Murphy, vice president, TLI.
  • Additionally, TLI sponsored a think tank session which served as a hub of innovation where emerging research on seizures, intracellular ferroptosis, GABA and purine signaling networks, thiamine deficiency, chronic pain relief and the groundbreaking Autism Knowledge Gateway were showcased.
  • The Autism Knowledge Gateway is a dynamic resource in development.
  • A collaborative chat room within the Gateway facilitates in-depth discussions of case studies and current research among clinicians.

Neurona Therapeutics Announces Publication in Cell Stem Cell Reporting the Development of Investigational Novel Regenerative Cell Therapy Strategy for Drug-resistant Focal Epilepsy

Retrieved on: 
Thursday, October 5, 2023

SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the publication of the development and characterization of a highly purified population of human stem cell-derived, pallial-specific MGE inhibitory interneurons for the potential treatment of focal epilepsy. In a preclinical study, administration of a single dose of the cells in a chronic model of drug-resistant MTLE resulted in durable and consistent suppression of focal seizures, as well as improvements in neuropathology and an increase in survival of the model. The study also demonstrated a potentially broad, safe and effective dosing range in the preclinical model. The data support the development of Neurona Therapeutics’ regenerative cell therapy candidate, NRTX-1001, which is being evaluated in an ongoing Phase I/II clinical trial of a one-time dose in subjects with drug-resistant MTLE (NCT05135091). The preclinical data were published today in Cell Stem Cell as a Clinical and Translational Report titled “Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy” by first authors Bershteyn, Bröer, Parekh, Maury, and colleagues and is available online.

Key Points: 
  • The data support the development of Neurona Therapeutics’ regenerative cell therapy candidate, NRTX-1001, which is being evaluated in an ongoing Phase I/II clinical trial of a one-time dose in subjects with drug-resistant MTLE ( NCT05135091 ).
  • The preclinical data were published today in Cell Stem Cell as a Clinical and Translational Report titled “Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy” by first authors Bershteyn, Bröer, Parekh, Maury, and colleagues and is available online .
  • “We are thrilled to announce this landmark publication, which builds the foundation for NRTX-1001 and exemplifies the phenomenal science being conducted by Neurona employees.
  • The data support the development of Neurona’s cell therapy candidate NRTX-1001, which is being evaluated in an ongoing clinical trial ( NCT05135091 ) in adults with drug-resistant MTLE.

Groundbreaking Study Finds Natural Formulation by MDbio – The Doctors BrandTM Significantly Improves Sleep, Anxiety, Stress, and Overall Well-being

Retrieved on: 
Tuesday, October 3, 2023

Los Angeles, CA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- In a momentous large-scale clinical trial, a MDSleep formulation by MDbio – The Doctors BrandTM was proven to significantly improve sleep compared to placebo.

Key Points: 
  • Los Angeles, CA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- In a momentous large-scale clinical trial, a MDSleep formulation by MDbio – The Doctors BrandTM was proven to significantly improve sleep compared to placebo.
  • Results showed the formulation enhanced sleep onset, and supported restful and healthy sleep.
  • Furthermore, the product led to significant improvements in feelings of anxiety, stress, and well-being compared to placebo.
  • This study was one of history’s largest double-blind randomized placebo controlled trials to demonstrate effectiveness of a non-melatonin supplement for improving sleep.

Get the Most Out of Your Last Days of Summer by Relaxing with Tea

Retrieved on: 
Tuesday, August 22, 2023

To get the most out of these last couple of weeks we recommend adding 1-2 cups of tea or herbal tea to your day to assist with relaxation.

Key Points: 
  • To get the most out of these last couple of weeks we recommend adding 1-2 cups of tea or herbal tea to your day to assist with relaxation.
  • While notable calming properties are associated with herbal tea infusions, there is also evidence for teas from the Camellia sinensis plant (white, green, oolong, black).
  • How Does Tea Promote Relaxation:
    Tea is a plant and a natural source of compounds like polyphenols, L-theanine, theaflavins, thearubigins, and gamma-aminobutyric acid (GABA).
  • With that in mind, the Tea & Herbal Association of Canada recommends trying a variety of teas and herbal teas to find what you like the taste of.

USANA continues its industry-leading scientific innovation by announcing three new products at Americas & Europe Convention

Retrieved on: 
Monday, August 14, 2023

It also includes an AM Energy Optimizer to promote energy and cognitive function, and a PM Sleep Optimizer that primes your body for restful and restorative sleep.

Key Points: 
  • It also includes an AM Energy Optimizer to promote energy and cognitive function, and a PM Sleep Optimizer that primes your body for restful and restorative sleep.
  • All of this is conveniently packaged in individual serving packets.
  • "Expanding our portfolio and creating new products is something that USANA strives for each and every day," said Dr.
  • "Our new nutrition line, Revolve, represents a holistic approach to supporting your body's natural circadian rhythm.

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Retrieved on: 
Tuesday, August 8, 2023

-- Company to host webcast to discuss findings of the Phase 1 study today, August 8, 2023, at 4:30pm ET

Key Points: 
  • Central target engagement, as the treatment group was easily identified in blinded data using qEEG power signature.
  • “The positive topline findings from our recently completed Phase 1 study of BMB-101, together with the observations from the qEEG portion of the study, validate our approach, as we continue to evaluate this important product candidate.
  • The Phase 1 study was conducted in Adelaide, Australia, by CMAX Clinical Research, a clinical trial center specializing in a range of early-phase trials and first-in-human studies.
  • The study evaluated the safety, tolerability, pharmacokinetic (PK), and food effect of BMB-101 in healthy volunteers.

Food and Drug Administration Approves First Postpartum Depression Pill, Research Led by Northwell Health’s Feinstein Institutes

Retrieved on: 
Monday, August 7, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230807136425/en/
    The national clinical trials for zuranolone were led by the Feinstein Institutes for Medical Research at Northwell Health.
  • “After years of dedicated research and collaboration with other scientists, women living with postpartum depression have a new, at-home, 14-day treatment option that has the potential to alleviate their symptoms,” said Dr. Deligiannidis.
  • Deligiannidis is a leader in clinical trials for postpartum depression, a condition that affects millions,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes, Karches Family Distinguished Chair in Medical Research.
  • “The FDA approval stemming from her work will make available new therapeutic options that are clearly needed.”
    The Feinstein Institutes and Dr. Deligiannidis lead in researching new methods to diagnose and treat perinatal depression.

Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Monday, August 7, 2023

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the second quarter ended June 30, 2023.
  • We plan to provide greater detail and next steps before the end of the third quarter,” continued Mr. Greene.
  • ZURZUVAE was approved by the FDA in August 2023 as the first-and-only oral treatment specifically indicated for adults with PPD.
  • Net Loss: Net loss was $160.3 million in the second quarter of 2023 compared to $126.3 million in the same period of 2022.

Relaxium® Enhances Customer Experience and Transparency with New Disclosures

Retrieved on: 
Wednesday, August 2, 2023

"We are committed to enhancing the customer experience when ordering our premium sleep aid," stated Timea Ciliberti, Founder and CEO at Relaxium®.

Key Points: 
  • "We are committed to enhancing the customer experience when ordering our premium sleep aid," stated Timea Ciliberti, Founder and CEO at Relaxium®.
  • "By focusing on transparency, explicit consent, and offering free trials for online subscriptions, we demonstrate our dedication to customer satisfaction."
  • By prioritizing the customer experience, Relaxium® strives to provide a seamless journey for individuals seeking restful sleep.
  • For more information about Relaxium®'s commitment to customer satisfaction and the high-quality ingredients used in Relaxium® Sleep, please visit www.tryrelaxium.com .